v3.26.3
BUSINESS AND LIQUIDITY (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
May 04, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
May 31, 2026
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Termination fee   $ 0 $ 0 $ 50,000 $ 0  
Cash, cash equivalents and marketable securities   $ 90,700   $ 90,700    
Pre-Merger Equityholders of Avenzo            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Merger valuation amount           $ 300,000
Avenzo Therapeutics, Inc | Pre-Merger Equityholders of Avenzo            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Merger and reorganization, combined ownership percentage           56.60%
Rallybio            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Concurred financing           $ 215,000
Rallybio | Pre-Merger Equityholders of Rallybio            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Merger and reorganization, combined ownership percentage           2.80%
Merger valuation amount           $ 15,000
Concurrent Financing | Pre-Merger Equityholders of Avenzo            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Merger and reorganization, combined ownership percentage           40.60%
Rallybio            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Termination fee $ 50,000          
Reimbursement of transaction costs $ 400          
Avenzo Therapeutics, Inc            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Concurred financing           $ 215,000